Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
Market Analysis and Insights: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market
The global Chemotherapy-Induced Nausea and Vomiting (CINV) market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
Report Includes
This report presents an overview of global market for Chemotherapy-Induced Nausea and Vomiting (CINV) market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Chemotherapy-Induced Nausea and Vomiting (CINV), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Chemotherapy-Induced Nausea and Vomiting (CINV), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chemotherapy-Induced Nausea and Vomiting (CINV) revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Chemotherapy-Induced Nausea and Vomiting (CINV) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Chemotherapy-Induced Nausea and Vomiting (CINV) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck, Eisai, ProStrakan, Helsinn Holding, Mundipharma, Qilu Pharma, Teva, Novartis and Heron Therapeutics, etc.
By Company
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Segment by Type
CINV
PONV
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Chemotherapy-Induced Nausea and Vomiting (CINV) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chemotherapy-Induced Nausea and Vomiting (CINV) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotherapy-Induced Nausea and Vomiting (CINV) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 CINV
1.2.3 PONV
1.3 Market by Application
1.3.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Perspective (2018-2029)
2.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Growth Trends by Region
2.2.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Region (2018-2023)
2.2.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Forecasted Market Size by Region (2024-2029)
2.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Dynamics
2.3.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Industry Trends
2.3.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Drivers
2.3.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Challenges
2.3.4 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Chemotherapy-Induced Nausea and Vomiting (CINV) by Players
3.1.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Players (2018-2023)
3.1.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Players (2018-2023)
3.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Chemotherapy-Induced Nausea and Vomiting (CINV), Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Concentration Ratio
3.4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue in 2022
3.5 Global Key Players of Chemotherapy-Induced Nausea and Vomiting (CINV) Head office and Area Served
3.6 Global Key Players of Chemotherapy-Induced Nausea and Vomiting (CINV), Product and Application
3.7 Global Key Players of Chemotherapy-Induced Nausea and Vomiting (CINV), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chemotherapy-Induced Nausea and Vomiting (CINV) Breakdown Data by Type
4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Type (2018-2023)
4.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecasted Market Size by Type (2024-2029)
5 Chemotherapy-Induced Nausea and Vomiting (CINV) Breakdown Data by Application
5.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Application (2018-2023)
5.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
6.2 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
6.2.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2018-2023)
6.2.2 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2024-2029)
6.2.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Type (2018-2029)
6.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application
6.3.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2018-2023)
6.3.2 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2024-2029)
6.3.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Application (2018-2029)
6.4 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
6.4.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2018-2023)
6.4.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
7.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
7.2.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2018-2023)
7.2.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2024-2029)
7.2.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Type (2018-2029)
7.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application
7.3.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2018-2023)
7.3.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2024-2029)
7.3.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Application (2018-2029)
7.4 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
7.4.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2018-2023)
7.4.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
8.2 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
8.2.1 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2018-2023)
8.2.2 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2024-2029)
8.2.3 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Type (2018-2029)
8.3 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application
8.3.1 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2018-2023)
8.3.2 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2024-2029)
8.3.3 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
9.2 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
9.2.1 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2018-2023)
9.2.2 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2024-2029)
9.2.3 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Type (2018-2029)
9.3 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application
9.3.1 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2018-2023)
9.3.2 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2024-2029)
9.3.3 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Application (2018-2029)
9.4 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region
9.4.1 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region (2018-2023)
9.4.3 Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
10.2.1 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application
10.3.1 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
10.4.1 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.1.4 Merck Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.1.5 Merck Recent Developments
11.2 Eisai
11.2.1 Eisai Company Details
11.2.2 Eisai Business Overview
11.2.3 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.2.4 Eisai Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.2.5 Eisai Recent Developments
11.3 ProStrakan
11.3.1 ProStrakan Company Details
11.3.2 ProStrakan Business Overview
11.3.3 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.3.4 ProStrakan Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.3.5 ProStrakan Recent Developments
11.4 Helsinn Holding
11.4.1 Helsinn Holding Company Details
11.4.2 Helsinn Holding Business Overview
11.4.3 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.4.4 Helsinn Holding Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.4.5 Helsinn Holding Recent Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Details
11.5.2 Mundipharma Business Overview
11.5.3 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.5.4 Mundipharma Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.5.5 Mundipharma Recent Developments
11.6 Qilu Pharma
11.6.1 Qilu Pharma Company Details
11.6.2 Qilu Pharma Business Overview
11.6.3 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.6.4 Qilu Pharma Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.6.5 Qilu Pharma Recent Developments
11.7 Teva
11.7.1 Teva Company Details
11.7.2 Teva Business Overview
11.7.3 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.7.4 Teva Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.7.5 Teva Recent Developments
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.8.4 Novartis Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.8.5 Novartis Recent Developments
11.9 Heron Therapeutics
11.9.1 Heron Therapeutics Company Details
11.9.2 Heron Therapeutics Business Overview
11.9.3 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.9.4 Heron Therapeutics Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.9.5 Heron Therapeutics Recent Developments
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.10.4 Roche Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.10.5 Roche Recent Developments
11.11 Mylan
11.11.1 Mylan Company Details
11.11.2 Mylan Business Overview
11.11.3 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.11.4 Mylan Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.11.5 Mylan Recent Developments
11.12 Tesaro
11.12.1 Tesaro Company Details
11.12.2 Tesaro Business Overview
11.12.3 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.12.4 Tesaro Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2018-2023)
11.12.5 Tesaro Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
*If Applicable.